MX2015014486A - Marcadores de respuesta de células tumorales a la terapia. - Google Patents

Marcadores de respuesta de células tumorales a la terapia.

Info

Publication number
MX2015014486A
MX2015014486A MX2015014486A MX2015014486A MX2015014486A MX 2015014486 A MX2015014486 A MX 2015014486A MX 2015014486 A MX2015014486 A MX 2015014486A MX 2015014486 A MX2015014486 A MX 2015014486A MX 2015014486 A MX2015014486 A MX 2015014486A
Authority
MX
Mexico
Prior art keywords
cancer
drug
patient
methods
treatment
Prior art date
Application number
MX2015014486A
Other languages
English (en)
Inventor
George D Yancopoulos
Gavin Thurston
David Frendewey
Gustavo Droguett
Matthew Koss
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2015014486A publication Critical patent/MX2015014486A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones y métodos para determinar biomoléculas en circulación antes, durante y/o después del tratamiento de un paciente con un fármaco (o fármaco putativo) contra el cáncer o contra tumores. También se proporcionan métodos de tratamiento basados en las composiciones y los métodos que se describen en la presente. Se proporcionan kits y métodos no invasivos para evaluar la eficacia de una terapia contra el cáncer para destruir o dañar células cancerosas. Se usan modalidades para determinar la eficacia en la destrucción del cáncer de un fármaco contra el cáncer en un paciente, optimizar la selección de un fármaco contra el cáncer para el tratamiento de un paciente, ajustar las dosis de un fármaco contra el cáncer para el tratamiento de un cáncer particular en un paciente y para identificar tratamientos útiles contra el cáncer para cualquier tipo particular de cáncer.
MX2015014486A 2013-04-15 2014-04-15 Marcadores de respuesta de células tumorales a la terapia. MX2015014486A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361812033P 2013-04-15 2013-04-15
PCT/US2014/034217 WO2014172376A2 (en) 2013-04-15 2014-04-15 Markers of tumor cell response to anti-cancer therapy

Publications (1)

Publication Number Publication Date
MX2015014486A true MX2015014486A (es) 2016-07-21

Family

ID=51686961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014486A MX2015014486A (es) 2013-04-15 2014-04-15 Marcadores de respuesta de células tumorales a la terapia.

Country Status (15)

Country Link
US (2) US10023916B2 (es)
EP (1) EP2986739B1 (es)
JP (1) JP2016518124A (es)
KR (1) KR20150140728A (es)
CN (1) CN105308189B (es)
AU (1) AU2014254091B2 (es)
BR (1) BR112015026095A8 (es)
CA (1) CA2909642A1 (es)
HK (1) HK1214630A1 (es)
MX (1) MX2015014486A (es)
MY (1) MY180365A (es)
RU (1) RU2664180C2 (es)
SG (2) SG11201508058TA (es)
WO (1) WO2014172376A2 (es)
ZA (1) ZA201507309B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9510569B2 (en) 2013-03-13 2016-12-06 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
SG11201508058TA (en) 2013-04-15 2015-10-29 Regeneron Pharma Markers of tumor cell response to anti-cancer therapy
CN104388561A (zh) * 2014-11-14 2015-03-04 浙江理工大学 肝癌生物标记物及其用途
CN106636315B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 淋巴瘤相关microRNA检测试剂盒
CN106636311B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 大肠癌相关microRNA检测试剂盒
WO2017207623A1 (en) * 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
CN105950768A (zh) * 2016-07-01 2016-09-21 江苏医诺万细胞诊疗有限公司 一种microRNA组合作为肿瘤标志物辅助诊断多种肿瘤的试剂盒及其检测方法
CN106350582B (zh) * 2016-08-25 2020-02-14 朱伟 一种与肺鳞癌辅助诊断相关的血清miRNA标志物及其应用
CN106282360B (zh) * 2016-08-31 2019-11-08 武汉博杰生物医学科技有限公司 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用
CN107913284B (zh) * 2016-10-09 2022-09-16 上海市东方医院 miRNA302-367簇的微小RNA在靶向抑制血管新生和肿瘤生长的应用
CN106778073B (zh) * 2017-01-19 2019-09-06 北京吉因加科技有限公司 一种评估肿瘤负荷变化的方法和系统
CN106834470A (zh) * 2017-02-17 2017-06-13 张灏 miRNA在制备癌症诊断试剂盒中的用途
CN106676196B (zh) * 2017-03-10 2019-05-07 上海核盾生物科技有限公司 一种用于诊断重度吸烟人群中肺鳞癌患者的非侵入性标记物及试剂盒
CN107326092B (zh) * 2017-08-25 2021-07-20 深圳市恩普电子技术有限公司 大肠癌相关的miRNA作为生物标志物的应用及大肠癌检测试剂盒
CN107858427B (zh) * 2017-10-24 2021-03-02 昆明理工大学 miR-429在制备乳腺癌诊断和检测试剂盒中的应用
CN108220381A (zh) * 2017-12-07 2018-06-29 国家卫生计生委科学技术研究所 试剂在制备药物中的用途以及筛选药物的方法
CN108531586B (zh) * 2018-03-19 2022-03-29 朱伟 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用
CN109097473A (zh) * 2018-08-24 2018-12-28 南京求臻基因科技有限公司 一种非小细胞肺癌辅助诊断试剂盒
KR102256747B1 (ko) * 2018-10-30 2021-05-25 가톨릭대학교 산학협력단 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도
CN109593852B (zh) * 2018-12-24 2022-03-08 朱伟 一种与鼻咽癌辅助诊断相关的血清miRNA标志物及其应用
WO2020232474A1 (en) * 2019-05-15 2020-11-19 The University Of Chicago Lactate response system and methods
CN110484620B (zh) * 2019-08-09 2023-09-19 深圳市第二人民医院 生物标志物及其在制备诊断ptmc的产品中的应用
KR102293777B1 (ko) * 2019-12-31 2021-08-25 연세대학교 산학협력단 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법
CN114214422B (zh) * 2020-03-30 2023-06-27 中国医学科学院肿瘤医院 外泌体miR-106b-3P、ARPC5在肺癌诊断中的应用
CN111808950B (zh) * 2020-06-02 2023-11-14 中南大学湘雅医院 一种甲状腺乳头状癌miRNA标志物及其应用
MX2022016232A (es) * 2020-06-19 2023-03-14 Agensys Inc Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
CN111676291B (zh) * 2020-07-14 2021-04-13 徐州医科大学 一种用于肺癌患病风险评估的miRNA标志物
CN113025713B (zh) * 2021-02-23 2022-11-22 浙江东睿生物科技有限公司 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
WO2024006581A1 (en) * 2022-07-01 2024-01-04 City Of Hope Biomarkers in colorectal cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059179A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceutical Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1786466B1 (en) 2004-06-18 2013-08-21 Genentech, Inc. Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
EP1951235B1 (en) 2005-09-20 2010-03-10 Scinopharm Singapore Pte, Ltd. Novel crystal forms of irinotecan hydrochloride
EP2369017B8 (en) * 2006-07-13 2014-03-12 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
EP2074226A2 (en) * 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008143795A1 (en) 2007-05-11 2008-11-27 Champions Biotechnology, Inc. Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing
AU2009219197B2 (en) * 2008-02-28 2014-04-10 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dep. Of Health And Human Services MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
WO2009147525A1 (en) * 2008-06-04 2009-12-10 Karolinska Institutet Innovations Ab Skin cancer associated micrornas
WO2010068473A1 (en) * 2008-11-25 2010-06-17 Gen-Probe Incorporated Compositions and methods for detecting small rnas, and uses thereof
WO2011040525A1 (ja) 2009-09-30 2011-04-07 財団法人ヒューマンサイエンス振興財団 大腸がん検査マーカーおよび大腸がんの検査方法
WO2011156777A1 (en) * 2010-06-10 2011-12-15 Fred Hutchinson Cancer Research Center Use of blood mir-210 for cancer prognosis
WO2012128902A1 (en) * 2011-03-18 2012-09-27 Baylor Research Institute Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
US20140228233A1 (en) 2011-06-07 2014-08-14 Traci Pawlowski Circulating biomarkers for cancer
WO2012174293A2 (en) * 2011-06-14 2012-12-20 Nestec Sa Methods for identifying inflammatory bowel disease patients with dysplasia or cancer
WO2014078850A1 (en) * 2012-11-19 2014-05-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of cancer diagnosis, progression and response to therapy using a primary xenograft mouse model for cancer serum biomarker discovery
SG11201508058TA (en) 2013-04-15 2015-10-29 Regeneron Pharma Markers of tumor cell response to anti-cancer therapy

Also Published As

Publication number Publication date
HK1214630A1 (zh) 2016-07-29
US20180291468A1 (en) 2018-10-11
WO2014172376A2 (en) 2014-10-23
US10023916B2 (en) 2018-07-17
BR112015026095A2 (pt) 2017-07-25
CA2909642A1 (en) 2014-10-23
EP2986739A2 (en) 2016-02-24
EP2986739A4 (en) 2017-03-01
RU2015148638A (ru) 2017-05-22
WO2014172376A3 (en) 2015-10-29
KR20150140728A (ko) 2015-12-16
BR112015026095A8 (pt) 2020-01-21
SG11201508058TA (en) 2015-10-29
SG10201708464TA (en) 2017-11-29
CN105308189B (zh) 2018-09-04
MY180365A (en) 2020-11-28
RU2664180C2 (ru) 2018-08-15
AU2014254091A1 (en) 2015-11-12
JP2016518124A (ja) 2016-06-23
ZA201507309B (en) 2017-08-30
EP2986739B1 (en) 2018-04-04
AU2014254091B2 (en) 2019-03-21
US20140308370A1 (en) 2014-10-16
CN105308189A (zh) 2016-02-03

Similar Documents

Publication Publication Date Title
MX2015014486A (es) Marcadores de respuesta de células tumorales a la terapia.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX344355B (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
BR112015021423A2 (pt) métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
PH12014502738A1 (en) High-xten fusion protein and its use in the treatment of growth hormone deficiency
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
ZA201800931B (en) Selection of patients for combination therapy
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
EA201691053A1 (ru) Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
WO2014052305A3 (en) Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
WO2016191703A3 (en) Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer